Further, Lieu et al. demonstrated that cell lines treated with foretinib and erlotinib or lapatinib [EGFR/human epidermal growth factor (HER) 2 inhibitor] synergistically inhibit HNSCC growth [100]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.